This free survey is powered by
  1. Surveys
  2. 2014
  3. February
  4. T
  5. Taiho Survey - La Ligue Nationale contre le Cancer
0%
Questions marked with an * are required
 
 
Thank you in advance for taking the time to complete this brief 10 question survey.

At the completion of your survey a €15 donation will be made to La Ligue Nationale contre le Cancer (National League Against Cancer) on your behalf.
 
 
 
* 1. Which best describes your specialty? (Choose one.)
 
Medical Oncology
 
Haematology
 
Haematology-Medical Oncology
 
Clinical Oncology (non-surgical)
 
Surgical Oncology
 
Other
 
 
 
 
* 2. What is the primary setting in which you see patients? (Choose one.)
 
Community practice (office or clinic)
 
Academic medical center
 
Hospital (non-government, non-academic)
 
Government hospital
 
Other
 
 
 
3. How many patients do you see each month for each of the following cancers?
(Please enter the approximate number below in the open field.)
* Metastatic colorectal cancer
* Small cell lung cancer
* Gastric cancer (stomach)
* Pancreatic cancer
* Metastatic breast cancer
 
 
4. On a scale of 1 -7, where 1 is completely unsatisfied, 4 is neutral, and 7 is completely satisfied, to what extent are your patients’ needs met with currently available chemotherapy for each of the following tumours? (Choose one number per tumor type.)
1 2 3 4 5 6 7 N/A
* Metastatic colorectal cancer
* Small cell lung cancer
* Gastric cancer (stomach)
* Pancreatic cancer
* Metastatic breast cancer
 
 
5. On a scale of 1 -7, where 1 is completely unfamiliar, 4 is neutral, and 7 is very familiar, how familiar are you with each of the following investigational agents for treating metastatic colorectal cancer? (Choose one number per agent.)
1 2 3 4 5 6 7
* HA-Irinotecan
* Ramucirumab
* TAS-102
* Imprime PGG
* BBI-608
 
 
6. On a scale of 1 -7, where 1 is not at all promising, 4 is neutral, and 7 is very promising, how promising are the following investigational agents for treating metastatic colorectal cancer? (Choose one number per agent.)
1 2 3 4 5 6 7 N/A
* HA-Irinotecan
* Ramucirumab
* TAS-102
* Imprime PGG
* BBI-608
 
 
 
* 7. Which of the following exhibitor booths did you visit at EORTC-NCI-AACR 2013 in Boston? (Choose all that apply.)
 
Boehringer Ingelheim
 
Crown Bioscience
 
GlaxoSmithKline Oncology
 
Taiho Oncology
 
Zalicus
 
Did not attend
 
Other
 

 
 
8. On a scale of 1 -7, where 1 is completely unfamiliar and 7 is very familiar, how familiar are you with each of the following investigational agents? (Choose one number per agent.)
1 2 3 4 5 6 7
* TAS-114 (A first-in-class dUTPase inhibitor with moderate inhibition of DPD)
* TAS-115 (A novel oral dual inhibitor of MET and VEGFR)
* TAS-116 (An orally available highly selective HSP90α and β inhibitor with a novel binding mode)
* TAS-117 (A novel orally available small-molecule allosteric inhibitor of AKT)
* TAS-119 (Potent, selective and orally available Aurora A inhibitor)
* TAS-120 (Novel irreversible and orally available FGFR inhibitor)
* TAS-121 (A novel orally available, mutant selective EGFR-TKI)
 
 
9. On a scale of 1 -7, where 1 is not at all promising, 4 is neutral, and 7 is very promising, which of the following mechanisms of action do you find most promising in the future treatment in your specialty? (Choose one number per agent.)
1 2 3 4 5 6 7 N/A
* dUTPase inhibitor that intensifies the effects of 5-FU
* Dual inhibitor of hepatocyte and vascular endothelial growth factor receptors (MET and VEGFR)
* HSP90α and β inhibitor
* Allosteric inhibitor of AKT
* Aurora A inhibitor
* FGFR inhibitor
* T790M mutant selective EGFR-TKI
 
 
 
10. Within the EU, who are some thought leaders in medical oncology you look to for guidance in the treatment of metastatic colorectal cancer? (Names and country, institution if known)